Free Trial

Bicara Therapeutics 3/25/2025 Earnings Report

Bicara Therapeutics logo
$13.03 -0.77 (-5.58%)
As of 03/25/2025 04:00 PM Eastern

Bicara Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Remove Ads

Bicara Therapeutics Earnings Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Bicara Therapeutics management to meet with Cantor Fitzgerald
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat